<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116411</article-id><article-id pub-id-type="publisher-id">ACM-43445</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_15359159.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  PHH3在膀胱尿路上皮癌中的表达及临床意义
  Expression and Clinical Significance of PHH3 in Urothelial Carcinoma of Bladder
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>侯</surname><given-names>四川</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2830</fpage><lpage>2835</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：膀胱癌是最常见的泌尿系统肿瘤，发病率及死亡率始终位于泌尿系统肿瘤首位。本研究通过对膀胱正常黏膜组织和尿路上皮癌组织中磷酸化组蛋白H3 (Phosphorylated Histone H3, PHH3)的表达情况，探讨其在膀胱尿路上皮癌中的表达与临床病理特征及预后的关系。方法：回顾性分析2016年1月至2020年1月期间在青岛市市立医院病理诊断为膀胱尿路上皮癌患者87例以及31例正常膀胱黏膜组织，使用免疫组化的方法分别检测PHH3在癌组织和正常粘膜组织中的表达情况，结合临床资料分析其表达与肿瘤的临床分期、病理分级、有无淋巴结转移之间的统计学关系。结果：PHH3蛋白定位于细胞核，呈棕黄色或棕褐色。在尿路上皮癌组织中PHH3表达阳性率为72%，在正常尿路上皮组织中阳性率为7%，差异有统计学意义(P &lt; 0.05)。在尿路上皮癌患者中，PHH3蛋白的表达与临床分期、病理分级、是否淋巴结转移有明显相关性，差异有统计学意义(P &lt; 0.05)，与患者年龄、性别未见明显关系，无统计学意义(P &gt; 0.05)。PHH3蛋白在一定程度上能判断膀胱癌进展状态和恶性程度，有较高的预后评估价值。
   Objective: Bladder cancer is the most common urinary system tumor, and its morbidity and mortality always rank first in urinary system tumors. In this study, through the expression of Phosphorylated Histone H3 (PHH3) in normal bladder mucosa tissues and urothelial carcinoma tissues, the relationship between the expression of Phosphorylated Histone H3 (PHH3) and clinicopathological characteristics and prognosis was investigated. Methods: A retrospective analysis of 87 patients with bladder urothelial carcinoma and 31 normal bladder mucosal tissues were pathologically diagnosed in Qingdao Municipal Hospital from January 2016 to January 2020. Immunohistochemistry was used to detect the expression of phh3 in cancer tissues and normal mucosa tissues. Combined with clinical data, the statistical relationship between its expression and clinical stage, pathological grade and lymph node metastasis was analyzed. Results: PHH3 is expressed in the cell nucleus and is brown or tan. The positive rate of PHH3 expression was 72% in urothelial carcinoma tissues and 7% in normal urothelial tissues, and the difference was statistically significant (P &lt; 0.05). In urothelial carcinoma patients, the expression of PHH3 protein was significantly correlated with the clinical stage, pathological grade and lymph node metastasis, with statistical significance (P &lt; 0.05). There was no significant relationship between age and gender of patients and no statistical significance (P &gt; 0.05). PHH3 protein can predict bladder cancer progression and malignancy to some extent, and has high prognostic value.
 
</p></abstract><kwd-group><kwd>膀胱尿路上皮癌，PHH3，免疫组化，预后, Bladder Urothelial Carcinoma</kwd><kwd> PHH3</kwd><kwd> Immunohistochemistry</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：膀胱癌是最常见的泌尿系统肿瘤，发病率及死亡率始终位于泌尿系统肿瘤首位。本研究通过对膀胱正常黏膜组织和尿路上皮癌组织中磷酸化组蛋白H3 (Phosphorylated Histone H3, PHH3)的表达情况，探讨其在膀胱尿路上皮癌中的表达与临床病理特征及预后的关系。方法：回顾性分析2016年1月至2020年1月期间在青岛市市立医院病理诊断为膀胱尿路上皮癌患者87例以及31例正常膀胱黏膜组织，使用免疫组化的方法分别检测PHH3在癌组织和正常粘膜组织中的表达情况，结合临床资料分析其表达与肿瘤的临床分期、病理分级、有无淋巴结转移之间的统计学关系。结果：PHH3蛋白定位于细胞核，呈棕黄色或棕褐色。在尿路上皮癌组织中PHH3表达阳性率为72%，在正常尿路上皮组织中阳性率为7%，差异有统计学意义(P &lt; 0.05)。在尿路上皮癌患者中，PHH3蛋白的表达与临床分期、病理分级、是否淋巴结转移有明显相关性，差异有统计学意义(P &lt; 0.05)，与患者年龄、性别未见明显关系，无统计学意义(P &gt; 0.05)。PHH3蛋白在一定程度上能判断膀胱癌进展状态和恶性程度，有较高的预后评估价值。</p></sec><sec id="s2"><title>关键词</title><p>膀胱尿路上皮癌，PHH3，免疫组化，预后</p></sec><sec id="s3"><title>Expression and Clinical Significance of PHH3 in Urothelial Carcinoma of Bladder<sup> </sup></title><p>Yang Feng, Sichuan Hou</p><p>Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/53-1572343x4_hanspub.png" /></p><p>Received: May 21<sup>st</sup>, 2021; accepted: Jun. 9<sup>th</sup>, 2021; published: Jun. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/53-1572343x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Bladder cancer is the most common urinary system tumor, and its morbidity and mortality always rank first in urinary system tumors. In this study, through the expression of Phosphorylated Histone H3 (PHH3) in normal bladder mucosa tissues and urothelial carcinoma tissues, the relationship between the expression of Phosphorylated Histone H3 (PHH3) and clinicopathological characteristics and prognosis was investigated. Methods: A retrospective analysis of 87 patients with bladder urothelial carcinoma and 31 normal bladder mucosal tissues were pathologically diagnosed in Qingdao Municipal Hospital from January 2016 to January 2020. Immunohistochemistry was used to detect the expression of phh3 in cancer tissues and normal mucosa tissues. Combined with clinical data, the statistical relationship between its expression and clinical stage, pathological grade and lymph node metastasis was analyzed. Results: PHH3 is expressed in the cell nucleus and is brown or tan. The positive rate of PHH3 expression was 72% in urothelial carcinoma tissues and 7% in normal urothelial tissues, and the difference was statistically significant (P &lt; 0.05). In urothelial carcinoma patients, the expression of PHH3 protein was significantly correlated with the clinical stage, pathological grade and lymph node metastasis, with statistical significance (P &lt; 0.05). There was no significant relationship between age and gender of patients and no statistical significance (P &gt; 0.05). PHH3 protein can predict bladder cancer progression and malignancy to some extent, and has high prognostic value.</p><p>Keywords:Bladder Urothelial Carcinoma, PHH3, Immunohistochemistry, Prognosis</p><disp-formula id="hanspub.43445-formula52"><graphic xlink:href="//html.hanspub.org/file/53-1572343x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/53-1572343x7_hanspub.png" /> <img src="//html.hanspub.org/file/53-1572343x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>膀胱癌是泌尿生殖系统最常见的恶性肿瘤，膀胱癌大多数起源于上皮组织，其中尿路上皮癌占90%以上。在世界范围内，膀胱癌的发病率占全部恶性肿瘤发病率的第十一位，每年约有15万人因膀胱癌而死亡 [<xref ref-type="bibr" rid="hanspub.43445-ref1">1</xref>]。引起膀胱癌的病因很多，但是多数病因尚不明确。现有研究表明苯胺类物质可导致膀胱癌的发生，其他诸如吸烟、慢性感染、饮食、药物、血吸虫病感染、家族史和生活方式等因素也与膀胱癌的发生有关 [<xref ref-type="bibr" rid="hanspub.43445-ref2">2</xref>]。目前膀胱癌治疗方法主要为经尿道膀胱肿瘤电切术(TURBT)和根治性膀胱切除术(RC)。但术后复发率极高，严重影响患者生存时间和生活质量。因此临床上对于膀胱尿路上皮癌预后影响因素的研究也逐渐被人们关注，寻找特异且敏感的预后指标意义重大。磷酸化组蛋白H3 (Phosphorylated Histone H3, PHH3)是真核细胞核心组蛋白，与细胞周期M期密切相关 [<xref ref-type="bibr" rid="hanspub.43445-ref3">3</xref>]，研究指出，组蛋白H3磷酸化主要发生在细胞有丝分裂期，而在细胞凋亡过程中不发生磷酸化，因此，PHH3可以作为细胞分裂的特异性标记，能一定程度上地反映细胞的增殖活性。而且最近的一些研究显示PHH3蛋白具有较高的预后价值 [<xref ref-type="bibr" rid="hanspub.43445-ref4">4</xref>]，是一种新的肿瘤预后预测指标 [<xref ref-type="bibr" rid="hanspub.43445-ref5">5</xref>]。本研究通过免疫组织化学法，检测肿瘤组织和正常组织中PHH3蛋白的表达，并分析其分别在癌组织与正常组织表达的关系、以及临床病理特征的关系，分析PHH3蛋白表达对膀胱尿路上皮癌的增殖活性的意义，进一步分析其对预后的影响。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取青岛市市立医院泌尿外科中心2016年1月至2020年1月期间因膀胱尿路上皮癌行手术的患者87例，经病理学确诊为尿路上皮癌且具有完整的临床资料。另选31例前列腺增生患者的新鲜膀胱组织，且经病理学诊断为正常膀胱组织作为对照。纳入标准：1) 首次诊断膀胱癌患者；2) 病理学检查确诊为膀胱尿路上皮癌；3) 患者的病历资料均详细及完整；4) 术前没有化疗或放疗等治疗；5) 没有家族性恶性肿瘤或其他同步恶性肿瘤的病史。排除标准：1) 转移性膀胱尿路上皮癌患者；2) 有其他恶性肿瘤病史患者；3) 临床资料缺失，失访患者；4) 初诊术前有过治疗患者。在87例膀胱尿路上皮癌患者中，男性65例，女性22例，确诊时的年龄范围42~85岁，平均年龄65岁。所有病例已获得病人的知情同意。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>将患者术后组织置于10%的福尔马林溶液中固定24 h后石蜡包埋。连续4 μm厚度切片。采用兔抗人PHH3多克隆抗体按照说明书进行免疫组化染色。PHH3为核表达蛋白，定位于细胞核，光学显微镜下可观察到细胞核中出现棕黄色或黄褐色颗粒则为阳性，无着色则为阴性。所有切片均由2名高年资病理医师采取随机双盲法在高倍视野下(&#215;400)进行判读。</p></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>采用SPSS 22.0软件对所得结果进行统计学分析。分类变量分析采取卡方检验。PHH3蛋白表达和复发之间关系通过Kaplan-Meier曲线分析，Log-rank检验。P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. PHH3蛋白在膀胱尿路上皮癌及癌旁正常组织中的表达</title><p>应用免疫组化方法检测87例膀胱尿路上皮癌组织和31例正常尿路上皮组织中PHH3蛋白的表达，PHH3免疫组化阳性产物主要见于尿路上皮细胞的细胞核中，表现为或棕褐色或棕黄色，见图1。</p><p>在87例尿路上皮癌组织中有63例PHH3表达为阳性，阳性率为72%，其中阴性有24例(28%)，在31例正常尿路上皮组织中有2例PHH3表达为阳性，阳性率为7%，其中阴性有29例(93%)。PHH3在尿路上皮癌组织阳性表达率(72%)与正常尿路上皮组织表达阳性率(7%)相比明显增高，差异有统计学意义(c2 = 40.194, P &lt; 0.05)，见表1，图1、图2。</p><p>图1. PHH3在尿路上皮癌中阳性表达</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Expression of phh3 in normal urothelial tissues and urothelial carcinoma tissue</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >PHH3表达</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >c<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >类型</td><td align="center" valign="middle" >阴性(−)</td><td align="center" valign="middle" >阳性(+)</td><td align="center" valign="middle" >合计</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >正常尿路上皮组织</td><td align="center" valign="middle" >29(93%)</td><td align="center" valign="middle" >2(7%)</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >40.194</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >尿路上皮癌组织</td><td align="center" valign="middle" >24(28%)</td><td align="center" valign="middle" >63(72%)</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. PHH3在正常尿路上皮组织和尿路上皮癌组织中的表达</p><p>图2. PHH3在正常尿路上皮组织和尿路上皮癌组织中的表达情况</p></sec><sec id="s7_2"><title>3.2. PHH3蛋白的表达与临床病理参数的关系</title><p>本次研究尿路上皮癌组织中PHH3蛋白表达情况与患者临床病理参数之间的关系。其中PHH3蛋白表达与临床分期、病理分级、有无淋巴结转移有关(P &lt; 0.05)。而与性别、年龄无统计学意义(P &gt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Relationship between phh3 expression and clinicopathological parameters of urothelial carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床病理参数</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  colspan="2"  >PHH3表达</th><th align="center" valign="middle"  rowspan="2"  >PHH3阳性率</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup></th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >阴性(−)</td><td align="center" valign="middle" >阳性(+)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001<sup> </sup></td><td align="center" valign="middle" >0.975</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >72%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >73%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.461</td><td align="center" valign="middle" >0.497</td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >69%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥65</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >76%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >临床T分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12.2</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Ta + T1</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >54%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T2~T4</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >88%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病理分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >24.526</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >I、II</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >52%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有无淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >94%</td><td align="center" valign="middle" >4.468</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >68%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. PHH3的表达与尿路上皮癌组织的临床病理参数的关系</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>作为泌尿系统最常见的恶性肿瘤，膀胱癌也是因癌症死亡因素中的第七大原因之一 [<xref ref-type="bibr" rid="hanspub.43445-ref6">6</xref>]。我国每年约有八万新诊断的膀胱癌患者，这其中约有75%是非肌层浸润性膀胱癌(NMIBC)，25%为肌层浸润性膀胱癌(MIBC)。NMIBC通常在膀胱镜检查时通过经尿道肿瘤电切术治疗，虽然患者在术后生存率方面预后良好，但有70%左右的复发风险，甚至约有10%~20%的几率进展为MIBC [<xref ref-type="bibr" rid="hanspub.43445-ref7">7</xref>]。相比之下，MIBC尽管进行了积极的治疗，但预后依然很差。因此，膀胱癌患者术后一般都需要定期随访。目前用于膀胱癌监测的生物标记物很少，仍然需要更敏感和特异性的生物标志物来增加对高复发率膀胱癌的检测，并识别那些有进展风险的患者，进一步评估患者预后。</p><p>恶性肿瘤通常是细胞分裂和增殖不受限制的结果。目前研究认为，肿瘤的发生是因为细胞周期的调控紊乱，从而导致细胞增殖失控。正常细胞有丝分裂周期是包括G1期、S期、G2期和M期 [<xref ref-type="bibr" rid="hanspub.43445-ref8">8</xref>]。PHH3可作为有丝分裂中具有特异性的标志物反映细胞增值活性。韩换 [<xref ref-type="bibr" rid="hanspub.43445-ref9">9</xref>] 研究结果示PHH3在胰腺神经内分泌肿瘤的表达与Ki67具有高度相关性，与Ki67比具有更多优势，可以协助Ki67对胰腺神经内分泌肿瘤进行病理诊断和分级。Aune等 [<xref ref-type="bibr" rid="hanspub.43445-ref10">10</xref>] 研究发现，PHH3在临床分期为III、IV期的卵巢癌中表达明显高于I、II期卵巢癌组，且伴有腹膜转移组的表达明显高于无转移组。Takahashi等 [<xref ref-type="bibr" rid="hanspub.43445-ref11">11</xref>] 研究表明，在胃癌中，PHH3表达水平明显增高，且和肿瘤血管浸润、淋巴转移等因素关系密切，而且PHH3水平高表达是胃癌患者预后较差的独立因素。而且在多种不同类型的肿瘤预后进行的相关研究中，PHH3被证明是多种肿瘤恶性程度及预后评估的潜在有力标志物 [<xref ref-type="bibr" rid="hanspub.43445-ref12">12</xref>]，能够一定程度的反映癌组织的增殖活性，对多种癌症具有较高的预后价值。</p><p>本次研究中，我们通过免疫组化法分别检测正常膀胱黏膜组织和膀胱尿路上皮癌组织中PHH3蛋白的表达，发现PHH3蛋白表达于细胞核。免疫组化结果显示：PHH3蛋白在尿路上皮癌和正常黏膜组织中的阳性率分别为72%和7%，两者差异有统计学意义，这与PHH3蛋白在其他肿瘤的相关研究结果相类似。</p><p>在膀胱尿路上皮癌患者中，我们通过免疫组化对不同病理特征患者癌组织中的PHH3蛋白进行定性和定量检测。结果显示PHH3蛋白在Ta + T1、T2~T4分期中阳性率分别为54%、88%，可以看出，随着肿瘤的浸润深度的增加，PHH3蛋白的阳性率也显著提高。PHH3在病理分级为I、II级患者中阳性率为52%，III级患者中阳性率高达为100%，而且III级患者组织中PHH3蛋白表达量明显高于I、II级患者，差异有统计学意义，病理分级越高，PHH3蛋白表达的阳性率也随着升高。在是否有淋巴转移方面，伴有淋巴结转移的患者PHH3阳性表达率(94%)明显高于无淋巴转移的患者(68%)，这也提示PHH3蛋白的高表达预示着患者有较高淋巴转移的倾向。以上实验结果可分析，对于临床分期高、病理分级差的患者来说，其膀胱癌组织中的PHH3蛋白阳性率更高，说明了PHH3蛋白的表达可能对膀胱癌的进展、浸润深度的增加有密切关系。也提示我们可以通过对患者PHH3蛋白的检测，可以评估肿瘤的组织学分级、预测淋巴结转移及其预后，可作为判断膀胱癌进展状态和恶性程度的指标。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，PHH3蛋白在膀胱尿路上皮癌中为高表达，并与膀胱尿路上皮癌的临床分期、病理分级、有无淋巴结转移之间密切相关。其阳性表达提示肿瘤恶性程度高、易复发、预后差，增加PHH3蛋白检测可进一步提高对膀胱癌患者预后情况的预测，指导治疗。</p></sec><sec id="s10"><title>文章引用</title><p>冯 阳,侯四川. PHH3在膀胱尿路上皮癌中的表达及临床意义Expression and Clinical Significance of PHH3 in Urothelial Carcinoma of Bladder[J]. 临床医学进展, 2021, 11(06): 2830-2835. https://doi.org/10.12677/ACM.2021.116411</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43445-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R., Miller, K., Goding Sauer, A., Fedewa, S., Butterly, L., Anderson, J., Cercek, A., Smith, R. and Jemal, A. (2020) Colorectal Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 145-164.  
&lt;br&gt;https://doi.org/10.3322/caac.21601</mixed-citation></ref><ref id="hanspub.43445-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Janković, S. and Radosavljević, V. (2007) Risk Factors for Bladder Cancer. Tumori, 93, 4-12.  
&lt;br&gt;https://doi.org/10.1177/030089160709300102</mixed-citation></ref><ref id="hanspub.43445-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Nowak, S. and Corces, V. (2004) Phosphorylation of Histone H3: A Balancing Act between Chromosome Condensation and Transcriptional Activation. Trends in Genetics: TIG, 20, 214-220. &lt;br&gt;https://doi.org/10.1016/j.tig.2004.02.007</mixed-citation></ref><ref id="hanspub.43445-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, P., Zhang, C., Yang, P., Chen, J., Liu, Y., Hu, H., Huang, H., Bao, Z., Zhang, W., Kong, W., et al. (2016) Phosphohistone H3 (pHH3) Is a Prognostic and Epithelial to Mesenchymal Transition Marker in Diffuse Gliomas. Oncotarget, 7, 45005-45014. &lt;br&gt;https://doi.org/10.18632/oncotarget.7154</mixed-citation></ref><ref id="hanspub.43445-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ribalta, T., McCutcheon, I., Aldape, K., Bruner, J. and Fuller, G. (2004) The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria. The American Journal of Surgical Pathology, 28, 1532-1536. &lt;br&gt;https://doi.org/10.1097/01.pas.0000141389.06925.d5</mixed-citation></ref><ref id="hanspub.43445-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yang, R., Liao, Z., Cai, Y. and Kong, J. (2018) LASP2 Suppressed Malignancy and Wnt/β-Catenin Signaling Pathway Activation In Bladder Cancer. Experimental and Therapeutic Medicine, 16, 5215-5223.  
&lt;br&gt;https://doi.org/10.3892/etm.2018.6836</mixed-citation></ref><ref id="hanspub.43445-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jacobs, B., Lee, C. and Montie, J. (2010) Bladder Cancer in 2010: How Far Have We Come? CA: A Cancer Journal for Clinicians, 60, 244-272. &lt;br&gt;https://doi.org/10.3322/caac.20077</mixed-citation></ref><ref id="hanspub.43445-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ladstein, R., Bachmann, I., Straume, O. and Akslen, L. (2010) Ki-67 Expression Is Superior to Mitotic Count and Novel Proliferation Markers PHH3, MCM4 and Mitosin as a Prognostic Factor in Thick Cutaneous Melanoma. BMC Cancer, 10, 140. &lt;br&gt;https://doi.org/10.1186/1471-2407-10-140</mixed-citation></ref><ref id="hanspub.43445-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">韩换. PHH3和NKX6-1在胰腺神经内分泌肿瘤中的表达及其意义[D]: [硕士学位论文]. 上海: 第二军医大学, 2017.</mixed-citation></ref><ref id="hanspub.43445-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Aune, G., Stunes, A., Tingulstad, S., Salvesen, O., Syversen, U. and Torp, S. (2011) The Proliferation Markers Ki-67/MIB-1, Phosphohistone H3, and Survivin May Contribute in the Identification of Aggressive Ovarian Carcinomas. International Journal of Clinical and Experimental Pathology, 4, 444-453.</mixed-citation></ref><ref id="hanspub.43445-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, H., Murai, Y., Tsuneyama, K., Nomoto, K., Okada, E., Fujita, H. and Takano, Y. (2006) Overexpression of Phosphorylated Histone H3 Is an Indicator of Poor Prognosis in Gastric Adenocarcinoma Patients. Applied Immunohistochemistry &amp; Molecular Morphology: AIMM, 14, 296-302. &lt;br&gt;https://doi.org/10.1097/00129039-200609000-00007</mixed-citation></ref><ref id="hanspub.43445-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Hendzel, M., Wei, Y., Mancini, M., Van Hooser, A., Ranalli, T., Brinkley, B., Bazett-Jones, D. and Allis, C. (1997) Mitosis-Specific Phosphorylation of Histone H3 Initiates Primarily within Pericentromeric Heterochromatin during G2 and Spreads in an Ordered Fashion Coincident with Mitotic Chromosome Condensation. Chromosoma, 106, 348-360.  
&lt;br&gt;https://doi.org/10.1097/00129039-200609000-00007</mixed-citation></ref></ref-list></back></article>